Rifamycin-induced lupus syndrome [8]

Lancet

Volumn 349, Issue 9064, 1997, Pages 1521-1522

  Berning, Shaun E ^a   Iseman, Michael D ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; ISONIAZID; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; EDEMA; FEMALE; HUMAN; LETTER; LUPUS ERYTHEMATOSUS; MALAISE; MALE; MYCOBACTERIOSIS; PRIORITY JOURNAL; PROVOCATION TEST; RAYNAUD PHENOMENON; RECURRENT DISEASE; RELAPSE;

EID: 0031011451     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62102-2     Document Type: Article

References (5)

1. Berning SE, Cook JL, Iseman MD. Drug-induced lupus syndrome associated with rifamycin therapy (abstract no 156). Clin Infect Dis 1995; 21: 746.
2. Peloquin CA. Antituberculosis drugs: pharmacokinetics. In: Heifets LB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991: 13-57.
3. Griffith DE, Brown BA, Girard WM, Wallace RJ. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex disease. Clin Infect Dis 1995; 21: 594-98.
4. Siegal FP, Eilbott D, Burger H, et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS 1990; 4:433-41.
5. McEvoy GK, ed. AHFS Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, 1996.